top of page
ELU Logo2 copy.jpg

CHANGING THE WORLD OF WOUND HEALING

Duck Dive.jpg

Eluciderm will
Improve the Lives of Billions Worldwide

Winner

WHS Woundshark 2024 INNOVATION AWARD

Eluciderm, Inc is proud to announce that Eluciderm has won the WHS WOUNDSHARK 2024 INNOVATION AWARD at the 2024 International Symposium for Advanced Wound Care (SAWC 2024). This award goes to the most innovative company in the wound healing space each year. The judges awarded the 2024 Wound Shark trophy to Eluciderm as recognition for the anticipated market impact of ELU42, a first-of-its-kind, topically administered, small-molecule drug designed to accelerate and enhance the healing of all wound types, including diabetic foot ulcers, third-degree burns, and traumatic open soft tissue wounds. The entire Eluciderm Team would like to thank WHS for this prestigious award as it works to bring the company’s novel series of therapeutics to market in the near future.

Slide3.jpeg

Healing in Every Drop

iStock-1137290947_edited.jpg

Eluciderm is revolutionizing regenerative medicine with therapeutics that enhance wound healing and minimize scarring after trauma.

 

Eluciderm has created novel, safe, and highly effective topically applied compounds for the treatment of wounds and burns to regenerate fully functional skin and cartilage. Healing time is faster and the repaired skin has superior tensile strength and elasticity, while dramatically reducing the formation of scar tissue.

• Burn victims can regenerate skin with reduced scarring.
 

• Diabetic patients with chronic wounds will experience wound healing and tissue regrowth.
 

• Surgery patients’ incisions will heal with stronger, more elastic skin with minimal scarring.
 

• Trauma victims and patients receiving cosmetic and reconstructive surgeries will heal with restored cartilage and collagen and reduced scarring.

iStock-458411711.jpg

Skin Regeneration
Anywhere / Anytime

Eluciderm’s compounds can be applied topically, taking treatment out of the hospital and allowing people to use it anywhere and anytime. Imagine being able to apply this life-changing therapy to burn victims at the scene of the fire, or even to injured astronauts in space.  

 

Our patented lead therapeutic candidate, ELU42, sets itself apart from injection-based therapeutics by being easier to administer, safer, and cheaper.

iStock-91508848.jpg

Scarless Wound Healing for Everyone

Our novel therapeutic prompts the regenerative healing of damaged skin and cartilage so that tissues return to their normal structure without the functional and aesthetic impairments associated with scarring (fibrosis).
 

Imagine:
 

  • freedom from the need to hide or feel ashamed behind disfigurement 

  • reduced suffering as a consequence of poorly healed and devastating wounds, burns and scars

  • the rise in global confidence when the trauma of living with disfiguring scars goes away.

  • humanity’s sigh of relief when life-changing wounds can simply be healed and forgotten
     

3 Breakthroughs

Behind Eluciderm

Cellular Intelligence

Our first breakthrough came from the insight that our skin cells have innate cellular instructions inside them. These instructions naturally direct the cell to produce either scar tissue or healthy skin. We call this Cellular Intelligence. 

Cellular Communication

Our next breakthrough was discovering how to communicate with our skin cells and “molecularly instruct” them to heal without promoting scarring.

We Have the Patent
on Topical Application

Our third breakthrough was developing our lead therapeutic candidate, ELU42, a formulation for topical and painless administration to wounds. ELU42 was recently approved by the USPTO and offers a novel approach to acute and chronic wound healing, as well as, regenerating damaged cartilage-across markets worth tens of billions of dollars annually.

Earth+from+Space.jpeg

Untapped Markets
Massive Opportunity

There are currently no FDA- approved scar preventative therapies available. Also, there are no cost effective and simple to administer drug therapies available to treat chronic wounds. Each unmet medical need represents a massive market opportunity.

Wound Types & Markets

2020: >$1B

Osteoarthritis 
(cartilage regeneration)

Chronic Wounds

2014: $96B

Traumatic Open Soft Tissue Wounds

$34.5 million nationally

$237 million worldwide

$4.8B Global cartilage repair market in 2018

Scar Treatments

2017: $19B

2023: (predicted) $32B

Cosmetic Surgeries

Global $50B by 2027

A Rare Opportunity to Impact Healing Around
the World

Eluciderm intends to capture as much of these available markets through an aggressive intellectual property strategy, by filing multiple compositions of matter and method of use patents for Eluciderm therapeutics.

 

We intend to take our recently patented lead molecule (ELU42) into human trials for three indications: diabetic foot ulcers, burns, and open soft tissue wounds.

Slide13.jpeg

Eluciderm Team

Daniel Holsworth, PhD, RAC (CEO)

Dr. Dan Holsworth is the Chief Executive Officer and founder of Eluciderm Inc. He is an entrepreneur, medicinal chemist and expert in the field of drug discovery with over 30 years of experience, including multiple stints in senior level research and director positions in the Biotech and Pharma industries, most notably Amylin Pharmaceuticals and Pfizer Global Research & Development. His research projects over the years have focused on a variety of therapeutic areas ranging from oncology, cardiovascular, metabolic, and inflammation, to more recent efforts in the fields of dermatology, and wound healing. His work has culminated in over half a dozen clinical candidates. He is the inventor on 30 patents and author of over 100 publications, book chapters, and presentations. Dr. Holsworth earned his doctorate in synthetic organic chemistry from Wayne State University in Detroit, Michigan, and was a Post-Doctoral Fellow in Medicinal Chemistry at Parke-Davis Pharmaceuticals in Ann Arbor, Michigan.

Sarika_edited.jpg

Sarika Saraswati, PhD (CSO)

Dr. Sarika Saraswati is the Chief Scientific Officer at Eluciderm Inc. She has more than 15 years of experience in studying biochemical and cellular aspects of human disease conditions that includes stem cells, regenerative medicine, wound healing and fibrosis. Currently, Dr. Saraswati also serves as a tenure track Assistant Professor at Tennessee State University with an adjunct appointment at Vanderbilt University Medical Center. Her research has been continuously funded by National Institute of Health, American Association of Blood Banks, and American Heart Association in addition to Internal grants at Vanderbilt. Dr. Saraswati has received multiple honors and awards including Young Investigator Award at the International Innovations in Wound Healing Conference and multiple first place awards in oral/poster presentation at International and National Conferences. Dr. Saraswati earned her Doctorate in Biochemistry and Molecular Biology from University of Arkansas for Medical Sciences, Little Rock, AR and her post-doctoral training at Vanderbilt University Medical Center, Nashville, TN.

John.jpg

​John P. Delgado, MD, FAAFM (CMO)

Dr. John P Delgado is the Chief Medical Officer and co-founder of Eluciderm, Inc.  He has over 30 years of both research and clinical experience in the areas of Clinical Research, Family Medicine, obstetrics, functional medicine, Stem Cell and Regenerative Medicine, procedural medicine, sports medicine and health administration. He is also a Medical Director and Principle Investigator at Velocity Clinical Research in both Grants Pass and Medford, Oregon. Dr. Delgado has served as Chief of Obstetrics and Perinatology in Ashland, Oregon, and has been the principle investigator in over 200 clinical studies, including major studies with Harvard University, the Cleveland Clinic, Mayo Clinic and several other private organizations. Dr. Delgado earned a Bachelor degree in Biological Sciences at Stanford University, attended UCLA Medical School is Board Certified in Family Medicine with memberships in the Institute of Functional Medicine and the American Academy of Stem Cell Physicians.

IMG_9041_edited.jpg

Joseph Marino (CBO)

Joseph Marino serves as a Chief Business Officer and co-founder of Eluciderm, Inc. For the past 40+ years he has embodied the entrepreneurial spirit with an unmatched series of startup-to-sale successes in the alternative/renewable/sustainable energy sector. His unique abilities as CEO/President to identify market potential and juggle both technical & leadership responsibilities have allowed him to repeatedly create forward-thinking products, build dynamic teams, and develop lucrative market segments. To date he has launched and sold four energy-based companies, and he continues to run a fifth. Always on the lookout for a new challenge, in 2020 Mr. Marino jumped at the opportunity to help Eluciderm navigate the business side of the biotech/pharmaceutical world. In addition to more technical pursuits, Mr. Marino is also an avid real estate investor; the crown jewel of his portfolio is the historic Noyo Harbor Inn, a 152-year-old boutique establishment on the stunning Mendocino Coast.

John J. Cummings III JD

Seed Investor
Board Member

Prominent former New Orleans-based trial lawyer and highly accomplished investor, Mr. Cummings now devotes much of his time and resources to philanthropic endeavors and the implementation of effective corporate strategy for Eluciderm.

Clinical Advisory Board

Screen Shot 2023-02-01 at 5.42.09 AM.png

Scientific Advisory Board

Screen Shot 2023-02-01 at 6.03.41 AM.png

Legal
(Patent Attorneys) Squire, Patton, and Boggs, LLP
(Corp) Morrison Foerster LLP
 

Eluciderm Board

Board2.png

Contact: Dan Holsworth, PhD, RAC

Founder & CEO, Eluciderm Inc.

San Diego, CA. USA

Thanks for submitting!

  • LinkedIn
bottom of page